Long-term insulin independence in type 1 diabetes mellitus using a simplified autologous stem cell transplant

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 5, 2016, Pages 2141-2148

  Cantú Rodríguez, Olga Graciela ^a   Lavalle González, Fernando ^a   Herrera Rojas, Miguel Ángel ^a   Jaime Pérez, José Carlos ^a   Hawing Zárate, José Ángel ^a   Gutiérrez Aguirre, César Homero ^a   Mancias Guerra, Consuelo ^a   González Llano, Oscar ^a   Zapata Garrido, Alfonso ^a   Villarreal Pérez, Jesús Zacarias ^a   Gómez Almaguer, David ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BIOLOGICAL MARKER; C PEPTIDE; CD34 ANTIGEN; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; ONDANSETRON; GLUCOSE BLOOD LEVEL; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALOPECIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG RESPONSE; FEMALE; FEVER; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MALE; MORBIDITY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; STEM CELL; VOMITING; AUTOTRANSPLANTATION; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84969754343     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2776     Document Type: Article

References (36)

1. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab. 2010;95:25-33.
2. Nerup J, Platz P, Andersen OO, et al. HL-A antigens and diabetes mellitus. Lancet. 1974;2:864-866.
3. Baekkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, Lernmark A. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature. 1982;298:167-169.
4. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39:481-497.
5. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicentre prospective registration study. Lancet. 2009;373:2027-2033.
6. Gómez-Díaz RA, Pérez-Pérez G, Hernández-Cuesta IT, et al. Incidence of type 1 diabetes in Mexico: Data from an institutional register 2000 edited. Diabetes Care. 2012;35:e77.
7. Dabelea D. The accelerating epidemic of childhood diabetes. Lancet. 2009;373:1999-2000.
8. Gregg BE, Moore PC, Demozay D, et al. Formation of a human β-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab. 2012;97:3197-3206.
9. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293-1300.
10. Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How does type 1 diabetes develop? The notion of homicide or β-cell suicide revisited. Diabetes. 2011;60:1370-1379.
11. Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: A cohort study. Lancet. 2008; 371:1777-1782.
12. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155:173-181.
13. Kent SC, Chen Y, Bregoli L, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature. 2005;435:224-228.
14. Noble JA, Valdes AM, Varney MD, et al. HLA class I and genetic susceptibility to type 1 diabetes: Results from the type 1 Diabetes Genetics Consortium. Diabetes. 2010;59:2972-2979.
15. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self-monitoring of blood glucose: Metaanalysis of randomised controlled trials using individual patient data. BMJ. 2011;343:3805.
16. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure? Blood. 2002;99:768-784.
17. Burt RK, Verda L, Oyama Y, Statkute L, Slavin S. Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin Immunopathol. 2004;26:57-69.
18. Openshaw H, Nash RA, McSweeney PA. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: Clinical review. Biol Blood Marrow Transplant. 2002;8:233-248.
19. Ikehara S, Ohtsuki H, Good RA, et al. Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation. Proc Natl Acad Sci U S A. 1985;82:7743-7747.
20. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568-1576.
21. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301:1573-1579.
22. Gu W, Hu J, Wang W, et al. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care. 2012;35:1413-1419.
23. D'Addio F, Valderrama Vasquez A, Ben Nasr M, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in newonset type 1 diabetes: A multicenter analysis. Diabetes. 2014;63:3041-3046.
24. Svahn BM, Remberger M, Alvin O, Karlsson H, Ringdén O. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant. 2012;47:706-715.
25. Cantú-Rodríguez OG, Jaime-Pérez JC, Gutiérrez-Aguirre CH, et al. Outpatient allografting using non-myeloablative conditioning: The Mexican experience. Bone Marrow Transplant. 2007;40:119-123.
26. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga Ldel C, et al. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transplant. 2003;9:157-161.
27. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33 Suppl 1:S11-S61.
28. Wolfsdorf JI. Multiple-component insulin regimens. In:Wolfsdorf JI, ed. Intensive Diabetes Management (ADA). American Diabetes Association 4th ed. Mexico: Wolters Kluwer; 2009, 99-100.
29. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69-82.
30. Snarski E, Milczarczyk A, Torosian T, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type 1. BMT. 2011;46:562-566.
31. Chan KW, Li CK, Worth LL, et al. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant. 2001;27:125-128.
32. Wu T, Levay-Young B, Heuss N, et al. Inducing tolerance to MHCmatched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy. Transplantation. 2002;74:22-27.
33. Keating MJ, O'Brien S, Plunkett W, et al. Fludarabine phosphate: A new active agent in hematologic malignancies. Semin Hematol. 1994;31:28-39.
34. Alarfaj AS, Khalil N. Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia. Clin Rheumatol. 2014;33:1731-1736.
35. Huong D, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheunatol. 2002;29:2571-2576.
36. Daikeler T, Tichelli A, Passweg J. Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res. 2012;71:439-444.